Predictive Oncology Inc.
POAI | NASDAQ
$4.91
+$0.29 (+6.28%)
At close: May 20, 2026, 12:45 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 125.28K | 1.62M | 1.63M | 1.51M | 1.42M | 1.25M |
Cost of Revenue | 72.62K | 826.14K | 609.21K | 505.11K | 487.02K | 447.19K |
Gross Profit | 52.66K | 797.68K | 1.02M | 1M | 933.66K | 805.08K |
Operating Income | -28.43M | -10.94M | -12.12M | -26.03M | -20.43M | -25.36M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -232.85M | -10.86M | -12.02M | -25.74M | -20.32M | -25.88M |
Net Income | -233.1M | -12.2M | -13.98M | -25.74M | -19.66M | -25.88M |
Selling & General & Admin | 26.33M | 8.89M | 9.06M | 12.47M | 11.71M | 10.94M |
Research & Development | 2.15M | 25.99K | 122.31K | 320.32K | 315.85K | 372.71K |
Other Expenses | n/a | 2.83M | 3.96M | 14.24M | 9.34M | 14.86M |
Operating Expenses | 28.48M | 11.74M | 13.14M | 27.03M | 21.36M | 26.17M |
Interest Expense | n/a | n/a | n/a | 10.65M | n/a | n/a |
Selling & Marketing Expenses | 406.25K | 1.47M | 1.49M | 1.36M | 774.53K | 584.94K |
Cost & Expenses | 28.55M | 12.56M | 13.75M | 27.54M | 21.85M | 26.61M |
Income Tax Expense | n/a | n/a | n/a | n/a | -661.66K | n/a |
Shares Outstanding (Basic) | 17.43M | 5.45M | 4.01M | 3.69M | 2.73M | 584.99K |
Shares Outstanding (Diluted) | 17.43M | 5.45M | 4.01M | 3.69M | 2.74M | 597.51K |
EPS (Basic) | -13.37 | -2.24 | -3.48 | -6.98 | -7.16 | -44.25 |
EPS (Diluted) | -13.37 | -2.24 | -3.48 | -6.98 | -7.20 | -44.25 |
EBITDA | -232.17M | -10.16M | -11.77M | -13.95M | -12.13M | -11.46M |
EBIT | -232.85M | -10.86M | -12.02M | -15.27M | -13.47M | -12.48M |
Depreciation & Amortization | 688.58K | 695.66K | 244.79K | 1.31M | 1.34M | 1.02M |
Add to Watchlist
Select watchlists to add or remove POAI